M-Vax: Phase II data; Phase III; marketed in Australia

AVXT said that in 2 Phase II trials in a total of 37 patients with stage IV melanoma (including 25 patients with visceral metastases) who had undergone complete tumor resection, M-Vax treatment gave a...